SCHEMBL17478992

SCHEMBL17478992

COC(=O)c1cc(S(=O)(=O)Cl)ccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
TSHR P16473 2/20 0.56
HPGD P15428 1/20 0.56
HSD17B10 Q99714 1/20 0.56
EPAS1 Q99814 1/20 0.45
CA2 P00918 5/20 0.42
ABL1 P00519 1/20 0.41
PKM P14618 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA9 Q16790 2/20 0.41
FLT1 P17948 1/20 0.40
FLT4 P35916 1/20 0.40
KDR P35968 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40
GAA P10253 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
YAP1 P46937 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3121869 0.87 ALDH1A1 (0.44) ALDH1A1TSHRHPGDHSD17B10EPAS1
SCHEMBL2642360 0.85 TSHR (0.58) ALDH1A1TSHRHPGDHSD17B10EPAS1
SCHEMBL29541454 0.85 ALDH1A1 (0.49) ALDH1A1TSHRHPGDHSD17B10CA2
SCHEMBL3362967 0.84 CA2 (0.58) ALDH1A1TSHRHPGDHSD17B10CA2
SCHEMBL14683630 0.83 TSHR (0.55) ALDH1A1TSHRHPGDHSD17B10EPAS1
SCHEMBL20766290 0.83 TSHR (0.55) ALDH1A1TSHRHPGDHSD17B10EPAS1
SCHEMBL1647307 0.82 CA2 (0.59) ALDH1A1TSHRHPGDHSD17B10CA2
SCHEMBL4904491 0.82 ALDH1A1 (0.47) ALDH1A1TSHRHPGDHSD17B10CA2
SCHEMBL18547926 0.82 ALDH1A1 (0.65) ALDH1A1TSHRHSD17B10CA2ABL1
SCHEMBL15352924 0.81 GAA (0.52) ALDH1A1TSHRHPGDHSD17B10EPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435092-B2 Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG 858 THERAPEUTICS, INC. (US) 2025-10-07 US disclosed
EP-4526304-A1 INHIBITORS OF PARG 858 Therapeutics, Inc. (US) 2025-03-26 EP disclosed
US-20240352018-A1 SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG 858 THERAPEUTICS, INC. 2024-10-24 US disclosed
US-11939335-B2 Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG 858 THERAPEUTICS, INC. (US) 2024-03-26 US disclosed
US-20230374022-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. 2023-11-23 US disclosed
US-20230374022-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. 2023-11-23 US disclosed
US-20230374022-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. 2023-11-23 US disclosed
WO-2023224998-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. (US) 2023-11-23 WO disclosed
WO-2023224998-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. (US) 2023-11-23 WO disclosed
CN-110511173-B Indole alkyl piperazine benzamide compound and application thereof 复旦大学 2023-06-23 CN disclosed
EP-3233848-B1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RES & DEV (FR) 2019-01-30 EP disclosed
US-20180265500-A1 TETRAHYDROQUINOLINE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-09-20 US disclosed
US-20180170869-A1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-06-21 US disclosed
US-20180170869-A1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-06-21 US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 US disclosed
EP-3174868-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS Nuevolution A/S (DK) 2017-06-07 EP disclosed
WO-2016097389-A1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-06-23 WO disclosed
WO-2016016316-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374022-A1 INHIBITORS OF PARG PARG, PLG, SERPINB1 ALDH1A1 4379/4885TSHR 4401/4885HPGD 45/4885
US-12435092-B2 Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG PARG, PLG, PTGIS ALDH1A1 3003/4885TSHR 3225/4885HPGD 50/4885
US-20180170869-A1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORB, RORA, RORC ALDH1A1 957/4885TSHR 228/4885HPGD 1233/4885
US-20240352018-A1 SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG PARG, PLG, PARN ALDH1A1 3174/4885TSHR 3670/4885HPGD 66/4885
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS BRD4, BRD3, BRDT ALDH1A1 3848/4885TSHR 3378/4885HPGD 2141/4885
US-20180265500-A1 TETRAHYDROQUINOLINE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC ALDH1A1 644/4885TSHR 256/4885HPGD 1020/4885
US-11939335-B2 Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG PARG, PTGIS, PLG ALDH1A1 2121/4885TSHR 3258/4885HPGD 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.